D9602-A方案长春新碱及更生霉素治疗儿童低风险胚胎型横纹肌肉瘤的疗效分析  

Efficacy of vincristine and dactinomycin chemotherapy according to D9602-A regimen in the treatment of children with low-risk embryonal rhabdomyosarcoma

作　　者：蔡炜嵩[1] 马赛男[1] 王倩[1] 陈欢欢[1] 吴荣[1] 

机构地区：[1]中国医科大学附属盛京医院肿瘤科,沈阳110004

出　　处：《实用药物与临床》2016年第8期945-948,共4页Practical Pharmacy and Clinical Remedies

摘　　要：目的提高对横纹肌肉瘤的认识,明确风险分组原则。探讨应用COG(儿童肿瘤协作组)D9602-A方案治疗我国儿童低风险组胚胎型横纹肌肉瘤的疗效及安全性。方法回顾性分析我院近年来收治的3例低风险胚胎型横纹肌肉瘤儿童患者资料,评估应用D9602-A方案长春新碱联合更生霉素治疗后的疗效及不良反应。结果 3例患儿均一般状态良好,无瘤生存。结论应用COG D9602-A方案治疗我国儿童低风险胚胎型横纹肌肉瘤疗效确切,患者耐受良好。Objective To further understand the rhabdomyosarcoma and make the risk grouping criteria clear, and to evaluate the therapeutic effect and safety of vincristine and dactinomycin chemotherapy according to D9602-A regimen in the treatment of children with low-risk embryonal rhabdomyosarcoma in China. Methods The data of three pediatric patients with low-risk embryonal rhabdomyosarcoma treated with vincristine and dactinomycin chemotherapy according to D9602-A regimen in our hospital in recent years were retrospectively analyzed, and the efficacy and side effects were evaluated. Results Three cases were all disease-free alive till now with good general performance. Con- clusion Vincristine and dactinomycin chemotherapy according to D9602-A regimen has good effect and good toler- ance in pediatric patients in China with low-risk embryonal rhabdomyosarcoma.

关 键 词：横纹肌肉瘤 化疗 长春新碱 更生霉素 

分 类 号：R738.7[医药卫生—肿瘤]